pharma supply chain Archives - Page 9 of 9 - rfxcel.com
Rfxcel Logo

Saudi Food and Drug Authority: A Quick Guide to Saudi Arabia’s Pharma Regulations

Saudi Arabia is the first of the six countries in the Gulf Cooperation Council to require drug traceability. Initiated by the Saudi Food and Drug Authority (SFDA), the Drug Track and Trace System (RDS) tracks all human registered drugs that are manufactured in Saudi Arabia or imported to the country.

SFDA is charged with ensuring the safety of human and veterinary drugs. It also oversees biological substances, chemicals, and electronic products. It has three primary objectives: preventing counterfeit drugs, improving drug availability, and achieving drug safety. To meet these goals, it is working to monitor all supply chain operations, gather reliable data about commonly counterfeited drugs, and utilizing technology (e.g., smartphones) so patients can get information about medications and receive real-time notifications about recalled drugs or similar warnings.

RDS is a standardized identification system that tracks drugs from the manufacturer to the patient. It adopts GS1 standards and applies to all pharmaceutical products on the Saudi market, including over-the-counter (OTC) medicines. According to GS1, Saudi Food and Drug Authority (SFDA) is working on similar requirements for medical devices and cosmetics.

Saudi regulations stipulate that all drugs must be marked with a GS1 Data Matrix barcode that contains, at minimum, the GS1 Global Trade Identification Number (GTIN), the expiry date, and the batch/lot number. This information must also be printed on labels. All transactions for drug packages must be reported to a national Drug Track & Trace System (DTTS), and all manufacturers licensed by the SFDA must acquire a Global Location Number (GLN).

Every registered drug in the Saudi market is assigned a Saudi Drug Code (SDC) that contains four variables: a fixed prefix, the year, a letter to identify the type of drug, and a serial number (e.g., SFDA12D001). The SDC will eventually replace the current code.

Furthermore, Saudi Food and Drug Authority will require products to be aggregated beginning October 1, 2019. All individual saleable units must be linked to the case they’re shipped in.

The SFDA and SDC requirements are complex and will be challenging for an array of stakeholders, including manufacturers, warehouses, and pharmacies. The aggregation requirement is particularly pressing, especially for companies that have not begun to prepare for the October deadline. To comply with the aggregation regulations, they’ll have to ensure their packaging lines are prepared, coordinate with trading partners, and have systems that can capture and report data to the DTTS.

rfxcel is ready to help your company comply with all Saudi regulations. We’re cultivating a presence in the region, including being an exhibitor at this year’s CPhI Middle East & Africa (MEA) conference in Abu Dhabi, United Arab Emirates. Our Traceability Platform (rTS) can help you keep track of all the products in your supply chain and ensure you’re complying with all SFDA and SDC requirements — or regulations in any country. Contact us for more information. Our supply chain experts are ready to help!

 

 

Comprehensive DSCSA Timeline: Prepping for DSCSA Compliance

Created as Title II of the Drug Quality and Security Act (DQSA), the Drug Supply Chain Security Act (DSCSA) is designed to prevent the introduction and distribution of counterfeit, stolen, contaminated, or otherwise harmful drugs in the United States. The DSCSA timeline has established requirements and deadlines to build an interoperable electronic system to identify and trace prescription drugs as they are distributed throughout the country.

In August 2023, the FDA announced a “stabilization period” that postponed enforcement of key requirements until November 27, 2024, giving pharma companies an extra year to prepare, get their systems running, and be ready for full compliance.

With this in mind, here’s a recap of the DSCSA timeline.

Understanding the DSCSA Timeline

The “end game” for the Drug Supply Chain Security Act is full interoperable electronic unit-level traceability (serialization) of every regulated drug in the United States. Key dates of the DSCSA timeline include the following:

      • November 27, 2013: DSCSA enacted
      • November 27, 2014: Third-party logistics providers (3PLs) must report licensure information to FDA annually
      • November 27, 2015: Manufacturers must print lot numbers on packaging
      • November 27, 2017: Manufacturers must serialize and verify products
      • November 27, 2018: Repackagers must serialize products
      • September 23, 2019: FDA delays enforcement of saleable returns requirement for wholesalers
      • November 27, 2019: Wholesalers/distributors can only receive and distribute serialized products
      • August 25, 2023: FDA announces extended stabilization period, postponing enforcement for one year
      • November 27, 2024: Start of stabilization period — FDA expects systems to be in place but delays enforcement
      • November 27, 2025: Full interoperable electronic unit-level traceability enforced for all stakeholders 

So, by November 27, 2024, manufacturers, wholesale distributors, dispensers (i.e., pharmacies, healthcare systems), repackagers, and 3PLs must have interoperable systems in place to share and verify package-level product identifier data electronically.

DSCSA Compliance Requirements

DSCSA compliance requirements vary by stakeholder, but it’s important to know how the regulations will affect both you and your trading partners.

The DSCSA requirements can be divided into several categories that apply to manufacturers, repackagers, wholesale distributors, dispensers, and 3PLs. Each is important, but four are particularly vital because they require these stakeholders to have specific systems in place to be fully compliant. These are what we’ve been calling the “four cornerstones” of DSCSA compliance:

Product identification (serialization)

Manufacturers and repackagers must put a unique product identifier (PI), such as a bar code, on certain prescription drug packages. This must be able to be read electronically.

Product tracing

Manufacturers, wholesale distributors, repackagers, and many dispensers (primarily pharmacies) must provide certain information about drug and who handled it each time it’s sold:

      • Transaction information (TI) includes the product name; its strength and dosage form; its National Drug Code (NDC); container size and number of containers; lot number; transaction date; shipment date; and the name and address of the businesses from which and to which ownership is being transferred.
      • The transaction statement (TS) is a paper or electronic attestation by the business transfer-ring ownership of the product that it has com-plied with the DSCSA.

Verification

Manufacturers, wholesale distributors, repackagers, and dispensers must establish systems and processes to verify PIs for certain prescription drugs packages. For saleable returns, manufacturers and wholesale distributors must use the Verification Router Service (VRS).

Authorized trading partners (ATPs)

All manufacturers, wholesale distributors, repackagers, 3PLs, and dispensers must be ATPs and be able to electronically verify that their trading partners are ATPs.

In broad terms, to be an ATP you must meet certain registration, licensing, and licensure reporting requirements under the Federal Food, Drug, and Cosmetic Act (FD&C Act) and comply with state licensing requirements. The definitions of ATP also include language about accepting or transferring direct ownership or possession of products.

Strategies for Compliance

Preparing for DSCSA compliance requires a lot of work, but it’s manageable with the right strategies and technologies. Start by understanding your role in the pharma supply chain and the specific requirements you’re expected to meet. Create a checklist for each requirement and make sure you have the resources needed to meet those standards.

The FDA made it clear that the stabilization period is not an excuse for pharma stakeholders to take a break from preparing. It’s quite the opposite, in fact: The Agency said the stabilization period was “not intended to provide, and should not be viewed as providing, a justification for delaying efforts by trading partners to implement the enhanced drug distribution security requirements.”

You can read the FDA’s official document about the stabilization period here.

Technology and DSCSA Compliance

Technology is your greatest ally when it comes to achieving and maintaining DSCSA compliance. During the stabilization period, companies need to assess their readiness and implement and test serialization and data-exchange solutions. Your solution must be capable of verifying product identifiers (serialized data), aggregation, and electronic data exchange.

Resources for Ongoing Compliance

There are numerous FDA and third-party resources that can assist with your compliance efforts.

This FDA webinar, entitled “Implementing DSCSA: Stabilization Period and Expectations,” is a good place to begin. The FDA’s main DSCSA page also includes numerous resources, as well as a link to sign up for email updates.

We also highly recommend our own DSCSA Compliance Library. It has links to our articles, webinars, white papers, and other resources that will help you better understand the DSCSA requirements.

Navigate the DSCSA Timeline with rfxcel

As the DSCSA timeline leads the industry to November 27, 2024, you’ll need to ensure that your organization is ready. That’s where we can help.

If you have questions about the DSCSA timeline and your obligations or are concerned that your current provider may not have the tools you need to comply, we encourage you to contact us today to speak with one of our DSCSA experts. We can provide you with the latest information and the solutions to protect consumers, identify suspect products, and maintain compliance.

DSCSA T3 Data Requirements: Track and Trace Software Solutions

Under the Drug Supply Chain Security Act (DSCSA), the T3 data for most medicines must be exchanged at change of ownership. The T3 data requirements includes the sending the Transaction history (TH), the Transaction information (TI), and the Transaction statement (TS).

Transaction History is a statement that details all information on all transactions for a product starting with the manufacturer. It is required until the final November 27, 2023, deadline.

Transaction Information includes the established name or names of the product, the strength and dosage form of the product, the national drug codes, the container, the number of containers, the lot number of the product, the date of the transaction, the date of the shipment. If more than 24 hours after the date of the transaction, the business names and address of the person from whom ownership is being transferred, and the business name and address of the person to whom ownership is being transferred.

Transaction Statement is a statement, in paper or electronic format, that states the partner is authorized to transfer ownership, received the product from an authorized entity, received the TI and  TS from the prior owner of the product, did not knowingly ship a suspect or counterfeit product, had systems and processes in place to comply with verification requirements, did not knowingly provide false TI, and did not knowingly alter the TH.

What do the T3 data requirements mean for me?

Manufacturers need to start the T3 data requirements process by providing all necessary information to the new owner in a electronic format. Wholesale distributors, repackagers, and even dispensers selling products to other dispensers without the medication going to a distinct patient, must continue to produce and transfer this T3 information as they exchange ownership. At the same time, wholesale distributors, repackagers, and dispensers cannot accept ownership of a product unless they are provided with associated T3 data. The T3 data requirements mandate all parties who have ownership of a product need to keep that product’s T3 data for 6 years.

For any member of the supply chain, if a product is thought suspect, or is found to be counterfeit, the product needs to be quarantined and investigated. The product’s ownership cannot be exchanged during the time that it is quarantined or investigated. If an FDA official requests information in relation to any drug recall, the member of the supply chain needs to be able to produce the T3 data, and in most circumstances, give it to the official within 48 hours.

Dispensers have separate regulations. Dispensers are currently required to accept and maintain transactional data for 6 years. By 2020 the DSCSA will require dispensers to verify the product identifier printed on at least 3 units or 10% of all units (whichever one is bigger), and match them to the recorded T3 data – if there are less than 3 packages, then all must be checked. By November 27, 2023, all pharmacies must have an electronic, interoperable system in place trace products at the package level.

Other Insights

Dispensers may enter into agreements with 3rd parties, where the 3rd party would store all T3 data. However, the dispenser is still responsible for producing all T3 data if a regulatory body makes a request. Relying on another partner, whose system is out of the dispenser’s control, may not be ideal. Many of these agreements only cover the products that 3rd party interacts with, requiring the dispenser to still track all T3 data for items that it received directly from a manufacturer or secondary wholesaler. Also, in 2020 dispensers will be required to check lot numbers regardless.

How rfxcel can help

rfxcel has been a leading traceability provider since 2003. Our expertise helps hundreds of customers achieve full regulatory compliance with the DSCSA. Our traceability system allows seamless integration with partner systems and provides no delays to your day-to-day business operations.

With DSCSA looming around the corner it is important to find a solutions provider who focuses on data integrity and flexibility. rfxcel’s system provides over a hundred data checks to ensure that there is no garbage data going in or going out, and with thousands of T3 data reports being created every day, ensuring that data is correct is top priority.

To learn more about the DSCSA, and how rfxcel can help you achieve compliance, click here.

Exploring Track and Trace for Pharmaceuticals: A Complete Guide

Track and trace for pharmaceuticals lets you pinpoint any item’s current and past locations in your supply chain in real time. It’s a powerful tool that no pharma company can do without, especially as more and more regulations mandate track and trace capabilities and specific requirements for recording and sharing supply chain data.

We’ve been doing track and trace for pharmaceuticals for 20 years, longer than any other solution provider serving the industry, and we thought now was a good time to revisit the fundamentals as part of our ongoing discussion about the pharma supply chain, evolving technologies, and regulatory compliance. Let’s take a look.

What is track and trace?

Track and trace is the ability to see everything in your supply chain.

Tracking means you’re able to see where something is now and where it is heading (e.g., a factory, a warehouse, a pharmacy or hospital). That “something” can be a pallet of items, individual boxes on that pallet, and the individual items inside each box.

Tracing means you’re able to see where an item has been and who has handled it (e.g., the date and time it arrived at a warehouse and when it was shipped to its final destination).

What is a track and trace system for?

A track and trace system comprises components that work together to ensure efficient product identification, data management, and communication. These components are crucial for accurate, real-time visibility and effective management throughout the supply chain. A track and trace system usually utilizes specialized software combined with product labeling, particularly barcodes (e.g., 2D DataMatrix codes) as unique identifiers, to achieve these capabilities.

What is track and trace for pharmaceuticals?

When designed and implemented correctly, a track and trace system for pharmaceuticals does exactly what its name promises. It tracks a drug, a vaccine, a medical device — anything in any configuration — as it moves forward through the supply chain and traces backward to reveal where it has been in the supply chain, all the way back to the individual ingredients or components that combined to create it.

Tracking lets pharmaceutical manufacturers keep tabs on every item in their supply chains as they are distributed. Its many benefits include optimizing operational efficiency and speed in the manufacturing process. It also protects against theft and diversion; monitors products in transit to help ensure they remain safe and environmentally stable; and prevent counterfeit, adulterated, or expired medications from entering the supply chain.

Traceability lets you follow the trail of anything in your supply chain. It is a key component in supply chain visibility and transparency. Its many benefits include fast and accurate recall management capabilities, brand protection, accurate inventory management, and building consumer/patient confidence.

Serialization for track and trace pharma

Track and trace for pharmaceuticals relies on a deliberate combination of technologies and processes. Its “building block” is serialization, which endows a product with a unique identity that allows it to be tracked and traced 24/7 and authenticated at any time (e.g., prior to sale, at dispensing, upon return, or during a recall).

Serialization also lets pharma companies “configure” their products to meet government regulations, many of which specifically mandate track and trace capabilities and related data requirements.

For example, the U.S. Drug Supply Chain Security Act (DSCSA) will require full serialization of the U.S. pharma supply chain on November 27 of this year (2023). Among other things, the law stipulates that a unique product identifier (PI), such as a barcode, must be placed on certain prescription drug packages, and that pharma companies must provide detailed information about a drug and who handled it each time it’s sold. (See below and read more about these and other requirements here.)

In Europe, a product’s data points are aggregated into a master database, the European HUB (EU HUB), as well as country-specific databases called the National Medicines Verification System (NMVS). In Russia, it’s the National Track and Trace Digital System (Chestny ZNAK).

Are track and trace regulations as common as serialization requirements?

Not every country with serialization requirements has track and trace requirements; however, regulators in many countries are starting to pair track and trace with serialization to achieve their goals, which include combating counterfeit, stolen, or adulterated drugs.

For example, as we said above, the DSCSA will require pharmaceutical stakeholders provide detailed information — transaction information (TI) and transaction statements (TS) — about a drug and who handled it each time it’s sold. Stakeholders at every node of the supply chain — from wholesalers to repackagers and dispensers — must receive an electronic copy of this data. They must also produce and add to the data if they sell the product.

Note: The DSCSA currently requires a third piece of data called the transaction history (TH). This is an electronic statement with the TI for every transaction going back to the manufacturer. However, TH will not be required after the November 2023 deadline.

Global compliance for track and trace in pharmaceuticals

In the pharmaceutical industry, track and trace systems are crucial for maintaining product integrity, combating counterfeit medications, and ensuring patient safety. To address these concerns, regulatory authorities worldwide have implemented stringent compliance requirements for track and trace in pharmaceuticals. Key aspects of global compliance requirements include serialization, product identification/authentication, traceability, electronic reporting to regulators, and electronic data-sharing among trading partners.

For more information about what countries require for track and trace for pharmaceuticals, check out our Global Compliance page. The regulatory landscape is constantly changing, so it’s the wise company that takes the time to keep up with requirements, changes, and deadlines.

Final thoughts: track and trace for pharmaceuticals

Track and trace for pharmaceuticals is no longer an option: It is a requirement for companies wanting to do business in key markets such as the United States, Europe, Russia, Brazil, the Middle East, Asia — virtually everywhere in the world. Put simply, not having a modern track and trace system is a huge risk.

As we said in our introduction, we’ve been doing pharmaceutical track and trace for 20 years. We were founded on the principle of making the pharma supply chain safer and protecting consumers through track and trace.

Today, we offer the industry’s most powerful track and trace solution. And now, as part of Antares Vision Group, we are confident that we offer the world’s most comprehensive solution for end-to-end supply chain track and trace connectivity. From L1 to L5, we have the hardware and software solutions that deliver all the benefits of track and trace for pharmaceuticals — or any product category.

Contact us today to talk to one of our supply chain experts or to schedule a demo of our award-winning Traceability System for the pharmaceutical industry. We want to make your supply chain your most valuable business asset.

Understanding Pharmaceutical Serialization Track and Trace: Enhancing Visibility and Safety

Serialization is the process of assigning predetermined codes to each unit or container of medication you manufacture. The code or serial number assigns each product item a digital identity, which you can track and trace as it progresses throughout the supply chain. Pharmaceutical serialization is a common type which is used to track and trace and provide supply chain visibility for pharmaceutical drugs.

When designing a codification system, you can make your serialization codes as detailed as government regulations necessitate.

Additionally, you can incorporate information like the date of production, when and where the item was manufactured, a lot or batch number, the stock-keeping unit (SKU), a drug or product description, and the manufacturer’s Global Trade Identification Number (GTIN).

Leading solutions also provide built-in code structure flexibility that can accommodate customized application identifiers (AIs). GS1, the internationally-recognized system of standards, created a dynamic definition of AIs that gives you the freedom to include a wealth of information in your code.

Now that we’ve addressed the question, “What is serialization,” let’s examine why it’s important to the pharmaceutical industry and how you can tap into significant organizational benefits by adopting modern serialization software.

What Is Pharmaceutical Serialization?

To adequately define serialization, we must not only consider the meaning of the term but also discuss why serializing products is a critical business management process.

Over the last several years, regulatory entities such as the European Medicine Agency (EMA) and the U.S. Food and Drug Administration (USFDA) have implemented significant changes to pharmaceutical regulations.

Why Is Serialization Important in the Pharmaceutical Industry?

The FDA’s Drug Supply Chain Security Act (DSCSA) is the most notable of these changes. While the DSCSA was passed in 2013, its final phase of provisions will come into force in late 2023. Among other things, this act requires that pharmaceutical products be serialized to promote traceability and preserve product integrity.

Serialization techniques may vary slightly from one nation to another. However, all labels will include some basic product information, regardless of the country of origin. 

For instance, a product label will typically include the following:

  • A unique serial number
  • A batch number
  • An expiration date
  • An identification code

Performing pharmaceutical serialization reduces the risks of harm associated with counterfeit medicines seeping into the market. Additionally, serializing medications allows regulatory authorities to hold violators accountable, preserve the integrity of the pharmacological supply chain, and protect consumers.

From your organization’s perspective, pharmaceutical serialization plays an important role in compliance. The aforementioned laws impose harsh penalties on entities that fail to comply with labeling and serialization requirements.

Looking Beyond Compliance: The Benefits of Pharmaceutical Serialization

Now that we’ve answered the question, “What does serialization mean” and touched on the growing importance of this tracking and identification method, let’s shift our attention to the benefits of implementing a serialization strategy.

Pharmaceutical serialization is an effective way of ensuring adherence to regulatory requirements and safety guidelines. Countless entities within the pharmaceutical space use serialization software for data validation and compliance purposes.

That said, compliance is just one benefit of pharmaceutical serialization. It can also assist with the following:

Supply Chain Visibility

The pharmacological supply and distribution network is one of the most complex in existence. Historically, this complexity has made achieving end-to-end supply chain visibility difficult.

While pharmaceutical serialization won’t entirely solve the industry’s visibility problem, it will certainly have a big impact on overall supply chain transparency. By equipping products with unique identifiers, manufacturers can track materials, ingredients, and finished products as they progress through the supply chain. 

Serialization enables manufacturers to closely manage their logistics processes. They can use these insights to pinpoint potential bottlenecks, increase supply chain efficiency, and ensure the timely delivery of goods to consumers.

Combating Counterfeiting

According to the Centers for Disease Control (CDC), approximately 9%–41% of medicinal products sold in low-to-mid-income nations are counterfeit.

Comparatively, less than 1% of pharmaceutical products sold in the U.S. are counterfeit. The FDA’s stringent labeling and serialization requirements are a major reason why counterfeit medicines aren’t a major issue in the U.S.

Expanding pharmaceutical serialization standards can help combat counterfeiting in less-developed low-income countries. Putting a stop to the distribution and sale of fraudulent products will also enable manufacturers to preserve their reputations in international markets.

Serialization gives retailers, distributors, and end users a means of discerning whether products are part of a legitimate batch of medication. Scannable codes are a particularly convenient and useful authentication tool, as they’re difficult for counterfeiters to fake.

Coordinating Product Recalls

Despite a manufacturer’s best efforts, medical devices and drugs sometimes must be recalled and taken out of circulation. Without an effective pharmaceutical serialization strategy in place, manufacturers must cast a wide net. This leads to significant waste, as safe, effective products are recalled and disposed of.

Properly executed pharmaceutical serialization helps manufacturers determine precisely which batches were impacted so they can reduce waste and limit the scope of recalls. Serialization and labeling also enable manufacturers to coordinate with government agencies to maximize the efficiency of recall efforts.

Monitoring Consumption Rates

Through serialization and labeling, manufacturers can track products from the factory to the point of consumption. They can leverage these insights to monitor each batch, examine consumption volume, and keep up with demand.

As demand wanes, manufacturers can adjust accordingly to preserve liquidity and avoid over-ordering raw materials. If consumer demand spikes suddenly, the manufacturer can scale production back up to prevent shortages and ensure that patients have access to essential medications.

Challenges to Serialization

As you can see, pharmaceutical serialization is a critical component of compliance. This process also has an impact on client satisfaction, patient safety, and your organization’s profitability.

Efficient serialization processes will enable you to adapt effectively to fluctuating consumer demand, protect your brand image, and optimize supply chain visibility. However, before you can unlock the benefits of pharmaceutical serialization, you must first overcome several challenges, including the following.

Aggregation

Data aggregation is key to promoting traceability and supporting the steady flow of goods across the pharmaceutical supply chain. Aggregation is the process of consolidating information from each participant in your supply chain into a unified, secure, and accessible database.

Let’s say your organization is the third link in the supply chain. The first is the raw material supplier, and the second is the carrier that delivers those materials to your facility.

When you receive the materials, you must assimilate the information from the supplier and carrier into your database. You also need to supplement this information with your own data.

Deadlines

Facing a rapidly approaching deadline can lead to a mad dash to modernize your pharmaceutical serialization protocols. Feeling the pressure of these deadlines will speed up your adoption process, right? Yes and no.

While you may be able to quickly adopt some new technology, waiting until the last minute can cause you to overlook essential steps during implementation. As a result, you’ll have to backtrack to fix gaps in your serialization strategy.

If you haven’t already begun implementing pharmaceutical serialization technology and processes, now is the time to start.

Repacking

Aggregating data will help you track and serialize whole boxes and pallets of products. But what happens if a customer needs a partial pallet or box? While you could raise your minimum order quantities (MOQ) to prevent this, doing so can deter purchases and negatively impact your sales volume.

When designing your serialization process, include an integrated repack phase so you can offer partial orders. When a picker scans the item serial numbers, the solution will repack the numbers and assign product data to the appropriate pallet or box.

Infrastructure

While you may already have serialization software, that platform likely lacks the scalability and flexibility of more modern solutions. As a result, you may not have the technological infrastructure necessary to support efficient pharmaceutical serialization.

The good news is the solution to this hurdle is relatively simple: replace your aging legacy technology with the world’s most scalable and robust serialization software from rfxcel.

Our leading-edge, flexible serialization solution can help you meet today’s labeling requirements and prepare for the unexpected regulatory challenges of tomorrow. Rfxcel not only provides you with dynamic software but also assists with the implementation process so you can maximize your ROI while minimizing the procedural hassle.

Expedite Your Serialization Implementation Process with rfxcel

With the final phase of the DSCSA rollout rapidly approaching, your organization must ensure that it has the right serialization software to support its compliance. Otherwise, you’ll find yourself struggling to meet the stringent requirements of the FDA’s latest drug safety and traceability provisions.

Serialization isn’t just crucial for pharmaceutical compliance. It also influences patient safety. By engaging in serialization, you can prevent bad actors from perpetrating your supply line and releasing illegitimate medications under your brand name.

Fraudulent activities endanger consumers and threaten your organization’s reputation. Fortunately, you can protect consumers, preserve your brand image, and ensure compliance with the DSCSA by partnering with a forward-thinking serialization software provider like rfxcel.

We offer a variety of labeling, tracing, and serialization solutions designed to meet the unique needs of the pharmaceutical sector. 

Contact rfxcel today to learn more about our suite of solutions.